TANG KEVIN C, Director, added 1,253,878 shares of La Jolla Pharmaceutical Company (LJPC) to its portfolio at the rate of $6.66 per share valuing $8,351,580 on Jan 13. The insider has now 7,910,575 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $7.39, with a 2nd Resistance Point sitting at $7.77. Meanwhile, this company’s stock has a 1st Support Level at $6.31 and a 2nd Support Level at $5.61. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of La Jolla Pharmaceutical Company (LJPC) was $7.00. La Jolla Pharmaceutical Company (LJPC) stock has gained $3.00, or 75.00%, in the past five days. In the last full month, these shares have gained $3.65, or 108.96%. In the past three months, this stock’s price has fallen by -$1.40, or -16.62%. This year-to-date, La Jolla Pharmaceutical Company (LJPC) shares have gained $3.07, or 78.12%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For La Jolla Pharmaceutical Company (LJPC) stock, 50% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Sell .”
With 27,157 K shares outstanding, this company currently has a market capitalization of $162,942K. La Jolla Pharmaceutical Company (LJPC) generates $10,060 K in annual sales, amounting to annual net income of -$199,470 K. This stock has generated a 1-Year Total Return of 6.87%, a 3-Year Total Return of -72.59%, and a 5-year Total Return of -69.88%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, La Jolla Pharmaceutical Company (LJPC) reported earnings of -$1.08 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$1.07 per share, representing a -0.01 difference and -0.93% surprise. In the previous quarter ending in 06/19, the reported earnings of -$1.12 represented equal from the consensus estimate calling for -$1.12 per share.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$1.00 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was -$0.90 and the low estimate was -$1.07. In the year-ago quarter, La Jolla Pharmaceutical Company (LJPC) generated per-share earnings of -$1.73. If the analysts are correct about the current quarter’s earnings, the growth will be +42.20%.
Turning our focus now to insider trading activity, there have been 19 purchases (2,909 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 43 insider buys amounting to 6,355 shares and 0 insider sales amounting to 0 shares. In the past full year, 97 insider purchases were made (involving 19,410 shares) and 0 insider sell-offs equivalent to 0 shares.
Moving onto liquidity, La Jolla Pharmaceutical Company (LJPC) has a Current Ratio of 5.95, a Quick Ratio of 5.88 and a Cash Ratio of 5.67. Looking at this company’s capital structure, its Total Debt to Total Equity is 346.10, its Total Debt to Total Capital is 77.58, and its Total Debt to Total Assets is now 60.86. Looking even further ahead into the future, its Long-Term Debt to Equity is -26.02 and its Long-Term Debt to Total Capital is 424.63.